Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

REGN vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

REGN vs. ILMN: Which Stock Is the Better Value Option?

Sridatri Sarkar headshot

TEM's Stable Solvency and Financial Strength Are Gaining Attention

by Sridatri Sarkar

Tempus AI posts a strong Q3 2025 balance sheet with $760M cash, no current debt, and positive adjusted EBITDA, boosting flexibility and solvency.

Zacks Equity Research

REGN vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

REGN vs. ILMN: Which Stock Is the Better Value Option?

Ekta Bagri headshot

Three Genomics Stocks Worth Tracking This Year

by Ekta Bagri

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.

Zacks Equity Research

Is This the Right Time to Add PBH Stock to Your Portfolio?

by Zacks Equity Research

Prestige Consumer Healthcare benefits from e-commerce momentum, acquisitions and solid solvency, even as inflation and tariff costs pose near-term risks.

Zacks Equity Research

Here's Why Illumina (ILMN) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Should Myriad Genetics Stock Stay in Your Portfolio Right Now?

by Zacks Equity Research

MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.

Zacks Equity Research

Should You Continue to Hold EXAS Stock in Your Portfolio Now?

by Zacks Equity Research

Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.

Zacks Equity Research

Should You Continue to Hold BRKR Stock in Your Portfolio?

by Zacks Equity Research

Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.

Sridatri Sarkar headshot

How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up

by Sridatri Sarkar

TEM sees modest Q3 reimbursement gains, but FDA and ADLT pathways for xT, xF and xR assays could narrow its pricing gap over 2025-2026.